Comparative Pharmacology
Head-to-head clinical analysis: CAMBIA versus INDOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMBIA versus INDOCIN.
CAMBIA vs INDOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating inflammation, pain, and fever.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.
50 mg orally once daily as needed for acute migraine, maximum 1 packet (50 mg) per 24 hours.
25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.
None Documented
None Documented
Terminal elimination half-life of diclofenac (active moiety) is approximately 1.9-2.1 hours. The clinical context: short half-life supports twice-daily dosing for acute pain.
Terminal elimination half-life approximately 4.5 hours (range 2.6–11.2 hours); prolonged in elderly and patients with hepatic impairment.
Approximately 50% of a dose is excreted in urine primarily as metabolites and conjugates, with less than 10% as unchanged drug. Biliary/fecal excretion accounts for about 40%.
Renal (60% as unchanged drug and glucuronide conjugates), biliary/fecal (33% via enterohepatic circulation).
Category C
Category C
NSAID
NSAID